Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib vs nilotinib plus interferon alpha in newly diagnosed chronic phase CML
2010-024262-22Phase 3Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- May 2012
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of nilotinib and peginterferon alfa-2b in chronic myelogenous leukemia (CML) (3 arms), sponsored by Friedrich Schiller University Jena. Primary endpoint: Major molecular response rate (MMR). Started May 2012; status: completed.
02
Drugs
nilotinibpeginterferon alfa-2b
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2010-024262-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024262-22.